BioticsAI, which won Disrupt’s Battlefield in 2023, will receive FDA approval for its AI-powered fetal ultrasound product.

TechCrunch hack The winner of the Battle of 2023, BioticsAIannounced on Monday that it has received FDA approval for its AI software which helps detect fetal abnormalities in ultrasound images.

The product was conceived by the main founder of Robhy Bustami, who grew up in a family of breeders, including his mother, aunt and uncle. She spent a lot of time in hospitals growing up, often traveling with her mother as she provided maternity care in the US

After studying writing and studying computer science at UC Irvine, Bustami collaborated with Salman Khan, Chaskin Saroff, and Dr. Hisham Elgammal in 2021 to start Results of BioticsAI.

The technology uses computer vision AI to “support fetal ultrasound quality assessment, anatomical fit, predictive reporting, and seamless integration into clinical workflow,” Bustami told TechCrunch.

He hopes his technology will help the US overcome the fact that the US has one of the worst outcomes for women. among high-income countries. Black women in particular face the highest rates of maternal mortality,

Bustami said that prenatal ultrasound has become the “cornerstone” of pregnancy monitoring, but its low-quality images can lead to wrong diagnoses.

Bustami said that the most difficult thing was not to create his AI models, which were trained on different types of hundreds of thousands of ultrasounds, but to ensure that the technology works reliably in the real world, especially for the population at high risk of tragic consequences.

“In areas where differences in treatment outcomes are well-documented, it was important to show consistency in patient groups, not just in positive cases,” Bustami continued.

The CEO said it took at least three years to go through the FDA process, including testing and certifying products. His experience taught him and his team how important it is to have engineering, sales, medicine, and management closely aligned from the very beginning. “By developing drugs, clinical validation, and regulatory processes together, rather than sequentially, we were able to move faster,” he said.

Now with FDA approval, Bustami said the company’s goal is to expand the range of healthcare systems across the country. They also have plans to expand into fetal medicine and reproductive health.

“We have the opportunity to expand distribution and clinical impact while continuing to develop our technology,” he said.

This piece was edited to correct the spelling of the co-founder’s name.